Stergios A. Polyzos

List of Publications by Year
in descending order

422	13,036	26630	38395
papers	citations	56 h-index	95 g-index

427	427	427	13933
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism: Clinical and Experimental, 2019, 92, 82-97.	3.4	679
2	Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism: Clinical and Experimental, 2011, 60, 313-326.	3.4	272
3	Nonalcoholic Fatty Liver Disease: The Pathogenetic Roles of Insulin Resistance and Adipocytokines. Current Molecular Medicine, 2009, 9, 299-314.	1.3	270
4	Clinical Features of 24 Patients With Reboundâ€Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases. Journal of Bone and Mineral Research, 2017, 32, 1291-1296.	2.8	270
5	Adipokines in nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2016, 65, 1062-1079.	3.4	250
6	The role of adiponectin in the pathogenesis and treatment of nonâ€alcoholic fatty liver disease. Diabetes, Obesity and Metabolism, 2010, 12, 365-383.	4.4	220
7	Leptin's Role in Lipodystrophic and Nonlipodystrophic Insulin-Resistant and Diabetic Individuals. Endocrine Reviews, 2013, 34, 377-412.	20.1	212
8	The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism: Clinical and Experimental, 2017, 71, 17-32.	3.4	208
9	Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia, 2016, 59, 30-43.	6.3	186
10	Pharmacotherapy of obesity: Available medications and drugs under investigation. Metabolism: Clinical and Experimental, 2019, 92, 170-192.	3.4	184
11	Irisin in patients with nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2014, 63, 207-217.	3.4	179
12	Leptin at the Intersection of Neuroendocrinology and Metabolism: Current Evidence and Therapeutic Perspectives. Cell Metabolism, 2013, 18, 29-42.	16.2	178
13	Irisin in metabolic diseases. Endocrine, 2018, 59, 260-274.	2.3	178
14	The Association Between Helicobacter pylori Infection and Insulin Resistance: A Systematic Review. Helicobacter, 2011, 16, 79-88.	3.5	175
15	Leptin in nonalcoholic fatty liver disease: A narrative review. Metabolism: Clinical and Experimental, 2015, 64, 60-78.	3.4	170
16	Eradication of Helicobacter pylori may be beneficial in the management of Alzheimerâ€™s disease. Journal of Neurology, 2009, 256, 758-767.	3.6	150
17	Extragastric Diseases and Helicobacter pylori. Helicobacter, 2015, 20, 40-46.	3.5	150
18	Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Endocrine, 2020, 67, 1-8.	2.3	150

#	Article	IF	Citations
19	Clinical complications following thyroid fineâ€needle biopsy: a systematic review. Clinical Endocrinology, 2009, 71, 157-165.	2.4	149
20	Pharmacotherapy of type 2 diabetes: An update. Metabolism: Clinical and Experimental, 2018, 78, 13-42.	3.4	144
21	Adipose tissue, obesity and non-alcoholic fatty liver disease. Minerva Endocrinology, 2017, 42, 92-108.	1.1	135
22	Circulating Irisin in Healthy, Young Individuals: Day-Night Rhythm, Effects of Food Intake and Exercise, and Associations With Gender, Physical Activity, Diet, and Body Composition. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3247-3255.	3.6	133
23	Relationship between Helicobacter pylori infection and glaucoma11The authors have no commercial interests in the products or devices mention herein.. Ophthalmology, 2001, 108, 599-604.	5.2	130
24	Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2013, 62, 121-126.	3.4	130
25	Sarcopenic obesity. Hormones, 2018, 17, 321-331.	1.9	129
26	Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology, 2012, 46, 272-284.	2.2	124
27	Irisin: A renaissance in metabolism?. Metabolism: Clinical and Experimental, 2013, 62, 1037-1044.	3.4	113
28	Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease. Archives of Medical Research, 2021, 52, 25-37.	3.3	112
29	Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal womenâ€"the six-month effect of risedronate and teriparatide. Osteoporosis International, 2012, 23, 1171-1176.	3.1	111
30	Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3Âmonths. Osteoporosis International, 2014, 25, 1633-1642.	3.1	111
31	Eradication of Helicobacter pylori May Be Beneficial in the Management of Chronic Open-Angle Glaucoma. Archives of Internal Medicine, 2002, 162, 1237.	3.8	103
32	Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial. Journal of Bone and Mineral Research, 2019, 34, 2220-2228.	2.8	103
33	Increased Cerebrospinal Fluid Helicobacter Pylori Antibody in Alzheimerâ€™s Disease. International Journal of Neuroscience, 2009, 119, 765-777.	1.6	96
34	Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota. Metabolism: Clinical and Experimental, 2017, 71, 182-197.	3.4	96
35	Circulating irisin levels and coronary heart disease: association with future acute coronary syndrome and major adverse cardiovascular events. International Journal of Obesity, 2015, 39, 156-161.	3.4	95
36	Five-year Survival After Helicobacter pylori Eradication in Alzheimer Disease Patients. Cognitive and Behavioral Neurology, 2010, 23, 199-204.	0.9	94

#	Article	IF	Citations
37	THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis. European Journal of Endocrinology, 2018, 179, R31-R45.	3.7	94
38	Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: A systematic review. Metabolism: Clinical and Experimental, 2016, 65, 1297-1306.	3.4	92
39	Serum thyrotropin concentration as a biochemical predictor of thyroid malignancy in patients presenting with thyroid nodules. Journal of Cancer Research and Clinical Oncology, 2008, 134, 953-960.	2.5	90
40	Review: Impact of Helicobacter pylori on Alzheimer's disease: What do we know so far?. Helicobacter, 2018, 23, e12454.	3.5	88
41	Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. Metabolism: Clinical and Experimental, 2020, 111, 154203.	3.4	88
42	The Emerging Role of Endocrine Disruptors in Pathogenesis of Insulin Resistance: A Concept Implicating Nonalcoholic Fatty Liver Disease. Current Molecular Medicine, 2012, 12, 68-82.	1.3	85
43	A potential impact of chronic Helicobacter pylori infection on Alzheimer's disease pathobiology and course. Neurobiology of Aging, 2012, 33, e3-e4.	3.1	83
44	Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study. Metabolism: Clinical and Experimental, 2019, 101, 154005.	3.4	83
45	H. pylori and Parkinsonâ€™s disease: Meta-analyses including clinical severity. Clinical Neurology and Neurosurgery, 2018, 175, 16-24.	1.4	78
46	Increased levels of Helicobacter pylori IgG antibodies in aqueous humor of patients with primary open-angle and exfoliation glaucoma. Graefe's Archive for Clinical and Experimental Ophthalmology, 2003, 241, 884-890.	1.9	77
47	Thyroid nodules - Stepwise diagnosis and management. Hormones, 2007, 6, 101-119.	1.9	74
48	Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement. Metabolism: Clinical and Experimental, 2019, 96, 66-82.	3.4	72
49	Alzheimerâ€™s disease and Helicobacter pylori infection: Defective immune regulation and apoptosis as proposed common links. Medical Hypotheses, 2007, 68, 378-388.	1.5	71
50	The Potential Adverse Role of Leptin Resistance in Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology, 2011, 45, 50-54.	2.2	69
51	Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab. Therapeutics and Clinical Risk Management, 2012, 8, 295.	2.0	69
52	Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2014, 63, 161-167.	3.4	69
53	New Aspects of Helicobacter pylori Infection Involvement in Gastric Oncogenesis. Journal of Surgical Research, 2008, 146, 149-158.	1.6	62
54	Nonalcoholic fatty future disease. Metabolism: Clinical and Experimental, 2016, 65, 1007-1016.	3.4	62

#	Article	IF	Citations
55	Obesity and thyroid cancer: epidemiologic associations and underlying mechanisms. Obesity Reviews, 2013, 14, 1006-1022.	6.5	61
56	Predictors of long-term remission in patients with Gravesâ€™ disease: a single center experience. Endocrine, 2013, 44, 448-453.	2.3	60
57	Challenge in the Pathogenesis of Autoimmune Pancreatitis: Potential Role of Helicobacter pylori Infection via Molecular Mimicry. Gastroenterology, 2007, 133, 368-369.	1.3	54
58	Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. Current Vascular Pharmacology, 2020, 18, 172-181.	1.7	54
59	Circulating irisin levels are lower in patients with either stable coronary artery disease (CAD) or myocardial infarction (MI) versus healthy controls, whereas follistatin and activin A levels are higher and can discriminate MI from CAD with similar to CK-MB accuracy. Metabolism: Clinical and Experimental, 2017, 73, 1-8.	3.4	53
60	Potential impact of Helicobacter pylori-related metabolic syndrome on upper and lower gastrointestinal tract oncogenesis. Metabolism: Clinical and Experimental, 2018, 87, 18-24.	3.4	53
61	The effect of teriparatide on serum Dickkopfâ€1 levels in postmenopausal women with established osteoporosis. Clinical Endocrinology, 2010, 72, 752-757.	2.4	52
62	Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis. Clinical Endocrinology, 2013, 79, 499-503.	2.4	52
63	Micro-Ultrasoundâ€“Guided vs Multiparametric Magnetic Resonance Imaging-Targeted Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-Analysis. Journal of Urology, 2021, 205, 1254-1262.	0.4	52
64	Induction of apoptosis as a proposed pathophysiological link between glaucoma and Helicobacter pylori infection. Medical Hypotheses, 2004, 62, 378-381.	1.5	51
65	Menopause and Non-Alcoholic Fatty Liver Disease: A Review Focusing on Therapeutic Perspectives. Current Vascular Pharmacology, 2019, 17, 546-555.	1.7	51
66	Primary open-angle glaucoma: pathophysiology and treatment. Lancet, The, 2004, 364, 1311-1312.	13.7	50
67	Helicobacter pylori and multiple sclerosis. Journal of Neuroimmunology, 2007, 188, 187-189.	2.3	50
68	An update on the validity of irisin assays and the link between irisin and hepatic metabolism. Metabolism: Clinical and Experimental, 2015, 64, 937-942.	3.4	50
69	Sex steroids and sex hormone-binding globulin in postmenopausal women with nonalcoholic fatty liver disease. Hormones, 2013, 12, 405-416.	1.9	49
70	Denosumab versus zoledronic acid in patients previously treated with zoledronic acid. Osteoporosis International, 2015, 26, 2521-2527.	3.1	49
71	Leptin in Health and Disease: Facts and Expectations at its Twentieth Anniversary. Metabolism: Clinical and Experimental, 2015, 64, 5-12.	3.4	49
72	Irisin: A true, circulating hormone. Metabolism: Clinical and Experimental, 2015, 64, 1611-1618.	3.4	48

#	Article	IF	Citations
73	Active Helicobacter pylori Infection is Independently Associated with Nonalcoholic Steatohepatitis in Morbidly Obese Patients. Journal of Clinical Medicine, 2020, 9, 933.	2.4	48
74	Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience. Pituitary, 2012, 15, 25-29.	2.9	47
75	Review article: nonâ€alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. Alimentary Pharmacology and Therapeutics, 2021, 54, 1013-1025.	3.7	47
76	A Systematic Review of Cases Reporting Needle Tract Seeding Following Thyroid Fine Needle Biopsy. World Journal of Surgery, 2010, 34, 844-851.	1.6	46
77	Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin and Dickkopf-1 Levels of Naive Postmenopausal Women With Low Bone Mass: A Randomized, Head-to-Head Clinical Trial. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3206-3212.	3.6	46
78	Gastrointestinal Immune System and Brain Dialogue Implicated in Neuroinflammatory and Neurodegenerative Diseases. Current Molecular Medicine, 2011, 11, 696-707.	1.3	45
79	Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name. Metabolism: Clinical and Experimental, 2020, 113, 154413.	3.4	45
80	New Molecular Concepts of Barrettâ€™s Esophagus: Clinical Implications and Biomarkers. Journal of Surgical Research, 2005, 125, 189-212.	1.6	44
81	Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2011, 12, 498-503.	1.7	44
82	Histological Presence of <i>Helicobacter pylori</i> Bacteria in the Trabeculum and Iris of Patients with Primary Open-Angle Glaucoma. Ophthalmic Research, 2012, 47, 150-156.	1.9	44
83	Emerging and future therapies for nonalcoholic steatohepatitis in adults. Expert Opinion on Pharmacotherapy, 2016, 17, 1937-1946.	1.8	42
84	Effects of combined lowâ€dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, nonâ€invasive indices of steatosis and fibrosis, and adipokine levels in nonâ€alcoholic fatty liver disease: <scp>a</scp> randomized controlled trial. Diabetes, Obesity and Metabolism, 2017, 19, 1805-1809.	4.4	41
85	Helicobacter pylori: an intruder involved in conspiring glaucomatous neuropathy. British Journal of Ophthalmology, 2009, 93, 1413-1415.	3.9	40
86	Denosumab Treatment for Juvenile Paget's Disease: Results From Two Adult Patients With Osteoprotegerin Deficiency (â€œBalkanâ€•Mutation in theTNFRSF11BGene). Journal of Clinical Endocrinology and Metabolism, 2014, 99, 703-707.	3.6	38
87	Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis. European Journal of Pharmacology, 2019, 863, 172661.	3.5	38
88	Alzheimerâ€™s disease and gastrointestinal microbiota; impact of Helicobacter pylori infection involvement. International Journal of Neuroscience, 2021, 131, 289-301.	1.6	38
89	Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study. International Journal of Clinical Practice, 2011, 65, 679-683.	1.7	37
90	Off-label uses of denosumab in metabolic bone diseases. Bone, 2019, 129, 115048.	2.9	37

#	Article	IF	Citations
91	A proposed role of human defensins in Helicobacter pylori-related neurodegenerative disorders. Medical Hypotheses, 2014, 82, 368-373.	1.5	36
92	Cardio-cerebrovascular disease and Helicobacter pylori-related metabolic syndrome: We consider eradication therapy as a potential cardio-cerebrovascular prevention strategy. International Journal of Cardiology, 2017, 229, 17-18.	1.7	36
93	Acromegaly: presentation, morbidity and treatment outcomes at a single centre. International Journal of Clinical Practice, 2011, 65, 896-902.	1.7	35
94	Clinical vertebral fractures following denosumab discontinuation. Endocrine, 2016, 54, 271-272.	2.3	35
95	Helicobacter pylori infection and esophageal adenocarcinoma: a review and a personal view. Annals of Gastroenterology, 2017, 31, 8-13.	0.6	33
96	Bone disease following solid organ transplantation: A narrative review and recommendations for management from The European Calcified Tissue Society. Bone, 2019, 127, 401-418.	2.9	33
97	Combination and sequential treatment in women with postmenopausal osteoporosis. Expert Opinion on Pharmacotherapy, 2020, 21, 477-490.	1.8	33
98	Normal-tension glaucoma and Alzheimerâ€™s disease: Helicobacter pylori as a possible common underlying risk factor. Medical Hypotheses, 2007, 68, 228-229.	1.5	32
99	Pituitary incidentalomas: a single-centre experience. International Journal of Clinical Practice, 2011, 65, 172-177.	1.7	32
100	Helicobacter pylori infection and Parkinsonâ€™s disease: apoptosis as an underlying common contributor. European Journal of Neurology, 2012, 19, e56.	3.3	32
101	Juvenile Paget disease. Metabolism: Clinical and Experimental, 2018, 80, 15-26.	3.4	32
102	Noninvasive Liver Fibrosis Tests in Patients with Nonalcoholic Fatty Liver Disease: An External Validation Cohort. Hormone and Metabolic Research, 2019, 51, 134-140.	1.5	32
103	From the â€œlittle brainâ€•gastrointestinal infection to the â€œbig brainâ€•neuroinflammation: A proposed fast axonal transport pathway involved in multiple sclerosis. Medical Hypotheses, 2009, 73, 781-787.	1.5	31
104	Upper Gastrointestinal Carcinogenesis: H. pylori and Stem Cell Cross-Talk. Journal of Surgical Research, 2011, 166, 255-264.	1.6	31
105	The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4155-e4162.	3.6	31
106	Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Pagetâ€™s disease of bone. Journal of Bone and Mineral Metabolism, 2008, 26, 635-641.	2.7	30
107	Guillain-BarrÃ© syndrome. Lancet Neurology, The, 2008, 7, 1080-1081.	10.2	30
108	RANKL inhibition for the management of patients with benign metabolic bone disorders. Expert Opinion on Investigational Drugs, 2009, 18, 1085-1102.	4.1	30

#	Article	IF	Citations
109	Effects of mastic gum Pistacia lentiscus var. Chia on innate cellular immune effectors. European Journal of Gastroenterology and Hepatology, 2009, 21, 143-149.	1.6	30
110	Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass. Bone, 2012, 50, 1130-1134.	2.9	30
111	EFFECT OF HELICOBACTER PYLORI ERADICATION ON HEPATIC STEATOSIS, NAFLD FIBROSIS SCORE AND HSENSI IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS: a MR imaging-based pilot open-label study. Arquivos De Gastroenterologia, 2014, 51, 261-268.	0.8	30
112	Circulating periostin levels in patients with AS: association with clinical and radiographic variables, inflammatory markers and molecules involved in bone formation. Rheumatology, 2015, 54, 908-914.	1.9	30
113	Selenium and selenoprotein P in nonalcoholic fatty liver disease. Hormones, 2020, 19, 61-72.	1.9	30
114	Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns. Metabolism: Clinical and Experimental, 2020, 104, 154144.	3.4	30
115	Circulating tumor necrosis factorâ€Î± levels in nonâ€alcoholic fatty liver disease: A systematic review and a metaâ€analysis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 3002-3014.	2.8	30
116	Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-ÎºB ligand levels in women with established osteoporosis treated with teriparatide. European Journal of Endocrinology, 2008, 158, 411-415.	3.7	29
117	Familial prevalence of autoimmune disorders in multiple sclerosis in Northern Greece. Multiple Sclerosis Journal, 2010, 16, 1091-1101.	3.0	29
118	Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index. Annals of Hepatology, 2013, 12, 749-757.	1.5	29
119	Helicobacter pylori infection, dementia and primary open-angle glaucoma: are they connected?. BMC Ophthalmology, 2015, 15, 24.	1.4	29
120	Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e390-e400.	3.6	29
121	Histological alterations following thyroid fine needle biopsy: A systematic review. Diagnostic Cytopathology, 2009, 37, 455-465.	1.0	28
122	Prevalence, bowel habit subtypes and medical care-seeking behaviour of patients with irritable bowel syndrome in Northern Greece. European Journal of Gastroenterology and Hepatology, 2009, 21, 183-189.	1.6	28
123	Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD). Metabolism: Clinical and Experimental, 2020, 111, 154318.	3.4	28
124	Helicobacter pylori may be involved in cognitive impairment and dementia development through induction of atrophic gastritis, vitamin B-12â€“folate deficiency, and hyperhomocysteinemia sequence. American Journal of Clinical Nutrition, 2007, 86, 805-806.	4.7	27
125	Serum vitamin B12 and folate levels in patients with non-alcoholic fatty liver disease. International Journal of Food Sciences and Nutrition, 2012, 63, 659-666.	2.8	27
126	Activin A and follistatin in patients with nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2016, 65, 1550-1558.	3.4	27

#	Article	IF	Citations
127	Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Pagetâ€™s disease. Journal of Bone and Mineral Metabolism, 2010, 28, 706-712.	2.7	26
128	Impact of reactive oxygen species generation on Helicobacter pylori-related extragastric diseases: a hypothesis. Free Radical Research, 2017, 51, 73-79.	3.3	26
129	Nonalcoholic fatty liver disease: Is it time for combination treatment and a diabetesâ€like approach?. Hepatology, 2018, 68, 389-389.	7.3	26
130	A perspective on risk factors for esophageal adenocarcinoma: emphasis on Helicobacter pylori infection. Annals of the New York Academy of Sciences, 2019, 1452, 12-17.	3.8	26
131	The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis. Bone, 2020, 138, 115478.	2.9	26
132	Helicobacter pylori and gastro-oesophageal reflux disease. Lancet, The, 2006, 368, 986.	13.7	25
133	Re: Helicobacter Pylori Infection and Colorectal Cancer Risk: Evidence From a Large Population-Based Case-Control Study in Germany. American Journal of Epidemiology, 2012, 176, 566-567.	3.4	25
134	The Effect of Leptin Replacement on Parathyroid Hormone, RANKL-Osteoprotegerin Axis, and Wnt Inhibitors in Young Women With Hypothalamic Amenorrhea. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2252-E2258.	3.6	25
135	New Aspects of Regulatory Signaling Pathways and Novel Therapies in Pancreatic Cancer. Current Molecular Medicine, 2008, 8, 12-37.	1.3	24
136	The Effect of Zoledronic Acid on Serum Dickkopf-1, Osteoprotegerin, and RANKL in Patients with Paget's Disease of Bone. Hormone and Metabolic Research, 2009, 41, 846-850.	1.5	24
137	Denosumab in treatment-naÃ¯ve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers. Metabolism: Clinical and Experimental, 2015, 64, 1291-1297.	3.4	24
138	Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease. Journal of Bone and Mineral Metabolism, 2016, 34, 447-456.	2.7	24
139	Obesity: seize the day, fight the fat. Metabolism: Clinical and Experimental, 2019, 92, 1-5.	3.4	24
140	ÂVaspin, resistin, retinol-binding protein-4, interleukin-1Î± and interleukin-6 in patients with nonalcoholic fatty liver disease. Annals of Hepatology, 2016, 15, 705-14.	1.5	24
141	Apoptotic and anti-angiogenic strategies in liver and gastrointestinal malignancies. Journal of Surgical Oncology, 2005, 90, 249-259.	1.7	23
142	Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial. International Journal of Clinical Practice, 2008, 62, 919-924.	1.7	23
143	Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis. Hormones, 2011, 10, 174-195.	1.9	23
144	The Emerging Role of Helicobacter Pylori-Induced Metabolic Gastrointestinal Dysmotility and Neurodegeneration. Current Molecular Medicine, 2018, 17, 389-404.	1.3	23

#	Article	IF	Citations
145	Helicobacter pylori infection and colorectal carcinoma: pathologic aspects. Journal of Gastrointestinal Oncology, 2012, 3, 377-9.	1.4	23
146	Nonalcoholic fatty liver disease: lifestyle and quality of life. Hormones, 2022, 21, 41-49.	1.9	23
147	Novel Advances in the Association Between Helicobacter pylori Infection, Metabolic Syndrome, and Related Morbidity. Helicobacter, 2015, 20, 405-409.	3.5	22
148	Similar late effects of a 7-week orthodox religious fasting and a time restricted eating pattern on anthropometric and metabolic profiles of overweight adults. International Journal of Food Sciences and Nutrition, 2021, 72, 248-258.	2.8	22
149	Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis. Hormones, 2002, 13, 519-31.	1.9	21
150	Alterations in Serum Thyroidâ€“Related Constituents After Thyroid Fine-Needle Biopsy: A Systematic Review. Thyroid, 2010, 20, 265-271.	4.5	21
151	Impact ofHelicobacter pylorion multiple sclerosis-related clinically isolated syndrome. Acta Neurologica Scandinavica, 2016, 133, 268-275.	2.1	21
152	A potential impact of Helicobacter pylori -related galectin-3 in neurodegeneration. Neurochemistry International, 2018, 113, 137-151.	3.8	21
153	Association between Active Helicobacter pylori Infection and Glaucoma: A Systematic Review and Meta-Analysis. Microorganisms, 2020, 8, 894.	3.6	21
154	Association between Helicobacter pylori infection and Guillainâ€BarrÃ© Syndrome: A metaâ€analysis. European Journal of Clinical Investigation, 2020, 50, e13218.	3.4	21
155	Impact of Helicobacter pylori-Related Metabolic Syndrome Parameters on Arterial Hypertension. Microorganisms, 2021, 9, 2351.	3.6	21
156	Coexistence of Gravesâ€™ disease, papillary thyroid carcinoma and unilateral benign struma ovarii: Case report and review of the literature. Metabolism: Clinical and Experimental, 2013, 62, 1350-1356.	3.4	20
157	Serum vaspin levels in women with and without gestational diabetes mellitus during pregnancy and postpartum. Cytokine, 2013, 61, 127-132.	3.2	20
158	Rodent models of obesity. Minerva Endocrinologica, 2020, 45, 243-263.	1.8	20
159	Serum homocysteine levels in patients with nonalcoholic fatty liver disease. Annals of Hepatology, 2012, 11, 68-76.	1.5	20
160	Nonlinear Distribution of Adiponectin in Patients With Nonalcoholic Fatty Liver Disease Limits Its Use in Linear Regression Analysis. Journal of Clinical Gastroenterology, 2010, 44, 229-230.	2.2	19
161	Adipocytokines in insulin resistance and non-alcoholic fatty liver disease: The two sides of the same coin. Medical Hypotheses, 2010, 74, 1089-1090.	1.5	19
162	Helicobacter pylori Infection Might Contribute to Esophageal Adenocarcinoma Progress in Subpopulations With Gastroesophageal Reflux Disease and Barrett's Esophagus. Helicobacter, 2012, 17, 402-403.	3.5	19

#	Article	IF	Citations
163	Circulating follistatin displays a dayâ€“night rhythm and is associated with muscle mass and circulating leptin levels in healthy, young humans. Metabolism: Clinical and Experimental, 2016, 65, 1459-1465.	3.4	19
164	Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment. Bone, 2019, 120, 44-49.	2.9	19
165	Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations. Maturitas, 2021, 147, 19-25.	2.4	19
166	A concept of Helicobacter pylori and stress-secreted mast cells' potential involvement in brain metastases. Journal of Neuroimmunology, 2009, 209, 121-122.	2.3	18
167	No Effect of Rosuvastatin in the Zoledronate-Induced Acute-Phase Response. Calcified Tissue International, 2011, 88, 402-408.	3.1	18
168	Role of wingless tail signaling pathway in osteoporosis. Current Opinion in Endocrinology, Diabetes and Obesity, 2011, 18, 383-388.	2.3	18
169	Novel aspects of defensinsâ€™ involvement in virus-induced autoimmunity in the central nervous system. Medical Hypotheses, 2017, 102, 33-36.	1.5	18
170	Selenoprotein P in Patients with Nonalcoholic Fatty Liver Disease. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, 598-602.	1.2	18
171	Comparative Effect of Atorvastatin and Rosuvastatin on 25-hydroxy-Vitamin D Levels in Non-diabetic Patients with Dyslipidaemia: A Prospective Randomized Open-label Pilot Study. Open Cardiovascular Medicine Journal, 2014, 8, 55-60.	0.3	18
172	Skeletal muscle mass and abdominal obesity are independent predictors of hepatic steatosis and interact to predict ten-year cardiovascular disease incidence: Data from the ATTICA cohort study. Clinical Nutrition, 2022, 41, 1281-1289.	5.0	18
173	Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease. Current Obesity Reports, 2022, 11, 166-179.	8.4	18
174	Combination Therapies for Nonalcoholic Fatty Liver Disease. Journal of Personalized Medicine, 2022, 12, 1166.	2.5	18
175	The Use of Demographic, Ultrasonographic and Scintigraphic Data in the Diagnostic Approach of Thyroid Nodules. Experimental and Clinical Endocrinology and Diabetes, 2009, 117, 159-164.	1.2	17
176	Helicobacter pylori with or without its neutrophil-activating protein may be the common denominator associated with multiple sclerosis and neuromyelitis optica. Multiple Sclerosis Journal, 2010, 16, 376-377.	3.0	17
177	Neuroprotection in glaucoma: Is there a future role of Helicobacter pylori eradication?. Experimental Eye Research, 2011, 92, 436-438.	2.6	17
178	Helicobacter pylori infection and the risk for cardiovascular disease. European Journal of Internal Medicine, 2011, 22, e146-e147.	2.2	17
179	Zoledronic acid-induced transient hepatotoxicity in a patient effectively treated for Pagetâ€™s disease of bone. Osteoporosis International, 2011, 22, 363-367.	3.1	17
180	Associations of Estrogen Receptor Alpha and Beta Gene Polymorphisms with Lipid Levels and Insulin Resistance in Men. Metabolism: Clinical and Experimental, 2015, 64, 611-617.	3.4	17

#	Article	IF	Citations
181	Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis. Expert Opinion on Investigational Drugs, 2015, 24, 145-157.	4.1	17
182	Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR-Î³ agonists. Metabolism: Clinical and Experimental, 2017, 66, 64-68.	3.4	17
183	Helicobacter pylori, gastric microbiota and gastric cancer relationship: Unrolling the tangle. World Journal of Gastrointestinal Oncology, 2022, 14, 959-972.	2.0	17
184	Subendothelial Carotid Hematoma After Fine-Needle Aspiration Biopsy of a Solitary Thyroid Nodule. Journal of Ultrasound in Medicine, 2008, 27, 1517-1520.	1.7	16
185	A novel noninvasive index for nonalcoholic steatohepatitis: a pilot study. Biomarkers, 2013, 18, 607-613.	1.9	16
186	Association between circulating irisin and homocysteine in patients with nonalcoholic fatty liver disease. Endocrine, 2015, 49, 560-562.	2.3	16
187	Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment. Expert Opinion on Therapeutic Targets, 2015, 19, 299-306.	3.4	16
188	Serum Adiponectin And Insulin-Like Growth Factor 1 In Predominantly Female Patients With Thyroid Cancer: Association With The Histologic Characteristics Of The Tumor. Endocrine Practice, 2016, 22, 68-75.	2.1	16
189	Helicobacter pylori infection and nonalcoholic fatty liver disease: Are the four meta-analyses favoring an intriguing association pointing to the right direction?. Metabolism: Clinical and Experimental, 2019, 96, iii-v.	3.4	16
190	Impact of Helicobacter pylori and/or Helicobacter pyloriâ€“related metabolic syndrome on incidence of allâ€cause and Alzheimerâ€§s dementia. Alzheimer's and Dementia, 2019, 15, 723-725.	0.8	16
191	Helicobacter pylori infection and nonalcoholic fatty liver disease: Time for large clinical trials evaluating eradication therapy. Helicobacter, 2019, 24, e12588.	3.5	16
192	Nonalcoholic fatty liver disease in males with low testosterone concentrations. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 1571-1577.	3.6	16
193	Comment on â€œEffect of biofilm formation by clinical isolates of Helicobacter pylori on the efflux-mediated resistance to commonly used antibioticsâ€• World Journal of Gastroenterology, 2017, 23, 6194-6196.	3.3	16
194	Hypophosphatasia. Journal of Clinical Medicine, 2021, 10, 5676.	2.4	16
195	Endogenous Intact PTH is Suppressed during Teriparatide (rhPTH 1-34) Administration in Postmenopausal Women with Established Osteoporosis. Endocrine Journal, 2008, 55, 613-616.	1.6	15
196	Adiponectin as a potential therapeutic agent for nonalcoholic steatohepatitis. Hepatology Research, 2010, 40, 446-447.	3.4	15
197	Pagetâ€™s Disease of Bone and Calcium Homeostasis: Focus on Bisphosphonate Treatment. Experimental and Clinical Endocrinology and Diabetes, 2011, 119, 519-524.	1.2	15
198	Helicobacter pylorimight contribute to nonalcoholic fatty liver disease-related cardiovascular events by releasing prothrombotic and proinflammatory factors. Hepatology, 2014, 60, 1450-1451.	7.3	15

#	Article	IF	Citations
199	Serum Levels of Activins, Follistatins, and Growth Factors in Neoplasms of the Breast: A Case-Control Study. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 349-358.	3.6	15
200	Eradication of Helicobacter pylori might halt the progress to oesophageal adenocarcinoma in patients with gastro-oesophageal reflux disease and Barrettâ€™s oesophagus. Medical Hypotheses, 2007, 68, 1174-1175.	1.5	14
201	Helicobacter pylori may hold a variable role in multiple sclerosis based on ethnicity. Medical Hypotheses, 2008, 71, 614-615.	1.5	14
202	Potential implications ofHelicobacter pylori-related neutrophil-activating protein. World Journal of Gastroenterology, 2012, 18, 489.	3.3	14
203	Acute transient thyroid swelling following needle biopsy: An update. Hormones, 2012, 11, 147-150.	1.9	14
204	Lipodystrophy: Time for a global registry and randomized clinical trials to assess efficacy, safety and cost-effectiveness of established and novel medications. Metabolism: Clinical and Experimental, 2017, 72, A4-A10.	3.4	14
205	Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease. European Journal of Pharmacology, 2021, 907, 174272.	3.5	14
206	Helicobacter pylori and glaucoma. Ophthalmology, 2003, 110, 2433-2434.	5.2	13
207	Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid. Supportive Care in Cancer, 2009, 17, 1329-1330.	2.2	13
208	Helicobacter pylori may be a common denominator associated with systemic and multiple sclerosis. Joint Bone Spine, 2011, 78, 222-223.	1.6	13
209	Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implications. Diabetes, Obesity and Metabolism, 2022, 24, 1702-1720.	4.4	13
210	Helicobacter pylori infection as a risk factor for primary open-angle glaucoma. Clinical and Experimental Ophthalmology, 2008, 36, 196-196.	2.6	12
211	Helicobacter pylori Might Contribute to Persistent Cognitive Impairment After Resolution of Overt Hepatic Encephalopathy. Clinical Gastroenterology and Hepatology, 2011, 9, 624.	4.4	12
212	Helicobacter pylori infection may trigger Guillainâ€“BarrÃ© syndrome, Fisher syndrome and Bickerstaff brainstem encephalitis. Journal of the Neurological Sciences, 2011, 305, 167-168.	0.6	12
213	Adiponectin in non-alcoholic fatty liver disease treatment: therapeutic perspectives and unresolved dilemmas. International Journal of Clinical Practice, 2011, 65, 373-374.	1.7	12
214	Helicobacter pylori Infection and Insulin Resistance. Helicobacter, 2013, 18, 165-166.	3.5	12
215	Polyautoimmunity in a Greek cohort of multiple sclerosis. Acta Neurologica Scandinavica, 2015, 131, 225-230.	2.1	12
216	Asymptomatic and normocalcemic hyperparathyroidism, the silent attack: a combo-endocrinology overview. Hormones, 2019, 18, 65-70.	1.9	12

#	Article	IF	Citations
217	Helicobacter pylori eradication regimens in an antibiotic highâ€resistance European area: A costâ€effectiveness analysis. Helicobacter, 2020, 25, e12666.	3.5	12
218	Potential impact of Helicobacter pylori-related Galectin-3 on chronic kidney, cardiovascular and brain disorders in decompensated cirrhosis. Digestive and Liver Disease, 2020, 52, 121-123.	0.9	12
219	Reconsidering the â€œprotectiveâ€•hypothesis of Helicobacter pylori infection in eosinophilic esophagitis. Annals of the New York Academy of Sciences, 2020, 1481, 59-71.	3.8	12
220	Thyroid dysfunction and non-alcoholic fatty liver disease. Minerva Endocrinology, 2018, 43, 367-376.	1.1	12
221	Menopausal hormone therapy in women with dyslipidemia and nonalcoholic fatty liver disease. Hormones, 2022, 21, 375-381.	1.9	12
222	Association between Helicobacter pylori infection and Alzheimerâ€™s disease in Japan. Journal of Neurology, 2011, 258, 2086-2086.	3.6	11
223	Is Serum IL-17A a Useful Systemic Biomarker in Patients With Langerhans Cell Histiocytosis?. Molecular Therapy, 2012, 20, 6-7.	8.2	11
224	Helicobacter pylori may play a role in both obstructive sleep apnea and metabolic syndrome. Sleep Medicine, 2012, 13, 212-213.	1.6	11
225	Impact of Helicobacter pylori Infection on Colon Oncogenesis. American Journal of Gastroenterology, 2013, 108, 625-626.	0.4	11
226	H elicobacter pylori-related ApoE 4 polymorphism may be associated with dysphagic symptoms in older adults. Ecological Management and Restoration, 2016, 29, 842-842.	0.4	11
227	Active Helicobacter pylori Infection Is a Risk Factor for Colorectal Mucosa: Early and Advanced Colonic Neoplasm Sequence. Gut and Liver, 2017, 11, 733-734.	2.9	11
228	Irisin: good or bad for the bone? A new path forward after the reported discovery of irisin receptor?. Metabolism: Clinical and Experimental, 2019, 93, 100-102.	3.4	11
229	Influence of Helicobacter pylori â€connected metabolic syndrome on nonâ€alcoholic fatty liver disease and its related colorectal neoplasm high risk. Liver International, 2020, 40, 475-476.	3.9	11
230	Helicobacter pylori infection as a potential risk factor for multiple sclerosis. Medical Hypotheses, 2020, 143, 110135.	1.5	11
231	Helicobacter pylori-Related Metabolic Parameters and Premalignant Gastric Mucosa Histological Lesions in Swiss Bariatric Patients. Microorganisms, 2021, 9, 1361.	3.6	11
232	Systematic review of cases reporting blood extravasation-related complications after thyroid fine-needle biopsy. Journal of Otolaryngology - Head and Neck Surgery, 2010, 39, 532-41.	1.9	11
233	Pathogenetic links between colorectal neoplasia and Barrett's esophagus. Gastrointestinal Endoscopy, 2006, 64, 298.	1.0	10
234	Effect of Strontium Ranelate on Lumbar Spine Bone Mineral Density in Women with Established Osteoporosis Previously Treated with Teriparatide. Hormone and Metabolic Research, 2009, 41, 559-562.	1.5	10

#	Article	IF	Citations
235	Pagetâ€™s disease of bone: emphasis on treatment with zoledronic acid. Expert Review of Endocrinology and Metabolism, 2009, 4, 423-434.	2.4	10
236	Impact of Helicobacter pylori on chronic hepatitis C-related cognitive dysfunction. Journal of Neuroimmunology, 2011, 233, 254-256.	2.3	10
237	Serum Osteoprotegerin, RANKL, and Dkk-1 Levels in Adults with Langerhans Cell Histiocytosis. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E618-E621.	3.6	10
238	Circulating fetuin-A in patients with pancreatic cancer: a hospital-based case-control study. Biomarkers, 2014, 19, 660-666.	1.9	10
239	Prevalence and determinants of type 2 diabetes mellitus in a Greek adult population. Hormones, 2016, 15, 88-98.	1.9	10
240	Adiponectin and vitamin D-binding protein are independently associated at birth in both mothers and neonates. Endocrine, 2018, 59, 164-174.	2.3	10
241	Impact of Helicobacter pylori and/or Helicobacter pyloriâ€related metabolic syndrome on gastroesophageal reflux diseaseâ€•Barrett's esophagusâ€•esophageal adenocarcinoma sequence. Helicobacter, 2018, 23, e12534.	3.5	10
242	Addressing the epidemic of fatty liver disease: A call to action, a call to collaboration, a call to moving the field forward. Metabolism: Clinical and Experimental, 2021, 122, 154781.	3.4	10
243	Molecular Links Between Alzheimer's Disease and Gastrointestinal Microbiota: Emphasis on Helicobacter pylori Infection Involvement. Current Molecular Medicine, 2019, 20, 3-12.	1.3	10
244	Induction of Interleukin-8 Expression by Helicobacter Pylori Infection in Patients with Endoscopy-Negative Gastroesophageal Reflux Disease. American Journal of Gastroenterology, 2004, 99, 2500-2501.	0.4	9
245	Multiple sclerosis and seizures: possible role ofHelicobacter pylori. European Journal of Neurology, 2011, 18, e116-e116.	3.3	9
246	Helicobacter pylori induced cognitive dysfunction might be associated with falls and fractures in cirrhosis. Hepatology, 2013, 57, 1284-1284.	7.3	9
247	Association betweenHelicobacter pyloriburden and Alzheimer's disease. European Journal of Neurology, 2014, 21, e100-e100.	3.3	9
248	The intriguing connections of leptin to hyperparathyroidism. Endocrine, 2017, 57, 376-387.	2.3	9
249	Acute Liver Failure. Journal of Clinical Gastroenterology, 2019, 53, 89-101.	2.2	9
250	Trimebutine Maleate Monotherapy for Functional Dyspepsia: A Multicenter, Randomized, Double-Blind Placebo Controlled Prospective Trial. Medicina (Lithuania), 2020, 56, 339.	2.0	9
251	Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 1913-1919.	3.6	9
252	Progression of Rebound-Associated Vertebral Fractures Following Denosumab Discontinuation Despite Reinstitution of Treatment: Suppressing Increased Bone Turnover May Not Be Enough. Journal of Clinical Densitometry, 2021, 24, 338-340.	1.2	9

#	Article	IF	Citations
253	The trimebutine effect on Helicobacter pylori-related gastrointestinal tract and brain disorders: A hypothesis. Neurochemistry International, 2021, 144, 104938.	3.8	9
254	Diabetes mellitus: 100â€¯years since the discovery of insulin. Metabolism: Clinical and Experimental, 2021, 118, 154737.	3.4	9
255	Microbes and Alzheimer' disease: lessons from H. pylori and GUT microbiota. European Review for Medical and Pharmacological Sciences, 2019, 23, 1845-1846.	0.7	9
256	Epidemiologic Analysis of Thyroid Fine Needle Aspiration Biopsies over a Period of 18 Years (1987â€“2004). Experimental and Clinical Endocrinology and Diabetes, 2008, 116, 496-500.	1.2	8
257	Greek and Israeli Patterns of Helicobacter pylori Infection and Their Association With Glaucoma: Similarities or Diversities?. Journal of Glaucoma, 2008, 17, 503-504.	1.6	8
258	No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial. Clinical Endocrinology, 2009, 70, 522-526.	2.4	8
259	Serum homocysteine, folate and vitamin B12 in patients with Pagetâ€™s disease of bone: the effect of zoledronic acid. Journal of Bone and Mineral Metabolism, 2010, 28, 314-319.	2.7	8
260	Helicobacter pylori may play an important role in both axonal type Guillainâ€“BarrÃ© syndrome and acute inflammatory demyelinating polyradiculoneuropathy. Clinical Neurology and Neurosurgery, 2011, 113, 520.	1.4	8
261	Helicobacter pyloriâ€“Related Impact on Glaucoma Pathophysiology. , 2015, 56, 8029.		8
262	Intracellular leptin signaling following effective weight loss. Metabolism: Clinical and Experimental, 2015, 64, 888-895.	3.4	8
263	Asporin levels are low in patients with nonalcoholic fatty liver disease and increase after vitamin E treatment. Hormones, 2019, 18, 519-521.	1.9	8
264	Impact of nitric oxide's bidirectional role on glaucoma: focus onHelicobacter pyloriâ€“related nitrosative stress. Annals of the New York Academy of Sciences, 2020, 1465, 10-28.	3.8	8
265	Impact of Helicobacter pyloriâ€linked metabolic syndrome on nonâ€alcoholic fatty liver disease and its connected atrial fibrillation risk. Liver International, 2020, 40, 2036-2037.	3.9	8
266	Treatment of nonalcoholic fatty liver disease with an anti-osteoporotic medication: A hypothesis on drug repurposing. Medical Hypotheses, 2021, 146, 110379.	1.5	8
267	Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation. Calcified Tissue International, 2021, 108, 587-594.	3.1	8
268	Helicobacter pylori Infection as a Risk Factor for Both Primary Open-Angle Glaucoma and Pseudoexfoliative Glaucoma in Thessaloniki Eye Study. American Journal of Ophthalmology, 2011, 152, 1079-1080.	3.3	7
269	Helicobacter pylori might be a potential therapeutic target in epilepsy. Medical Hypotheses, 2011, 76, 763.	1.5	7
270	Papillary thyroid microcarcinoma presenting as lymph node metastasis â€“ a diagnostic challenge: case report and systematic review of literature. Hormones, 2012, 11, 419-427.	1.9	7

#	Article	IF	Citations
271	Potential Oncogenic Properties of Mobilized Stem Cells in a Subpopulation of Inflammatory Bowel Disease Patients Infected with Helicobacter pylori. Inflammatory Bowel Diseases, 2013, 19, E27-E29.	1.9	7
272	Aquaporin 4, Helicobacter pylori and potential implications for neuromyelitis optica. Journal of Neuroimmunology, 2013, 263, 162-163.	2.3	7
273	Helicobacter pylori infection, insulin resistance and nonalcoholic fatty liver disease. Medical Hypotheses, 2014, 82, 795.	1.5	7
274	Fetuin-A levels and free leptin index are reduced in patients with chronic lymphocytic leukemia: a hospital-based case-control study. Leukemia and Lymphoma, 2016, 57, 577-584.	1.3	7
275	Helicobacter pylori â€“related metabolic syndrome as predictor ofÂprogression to esophageal carcinoma in a subpopulation-based Barrettâ€™s esophagus cohort. Gastrointestinal Endoscopy, 2017, 85, 462-463.	1.0	7
276	Multiple Vertebral Fractures Following Denosumab Discontinuation: Are We Exaggerating?. Calcified Tissue International, 2018, 103, 107-108.	3.1	7
277	Free IGF-1, Intact IGFBP-4, and PicoPAPP-A are Altered in Acute Myocardial Infarction Compared to Stable Coronary Artery Disease and Healthy Controls. Hormone and Metabolic Research, 2019, 51, 112-119.	1.5	7
278	Treatment of nonalcoholic fatty liver disease: from adult trials to perspectives in the management of children and adolescents. Expert Opinion on Pharmacotherapy, 2020, 21, 247-251.	1.8	7
279	Efficacy of Antiosteoporotic Medications in Patients With Rebound-Associated Fractures After Denosumab Discontinuation. Journal of Clinical Densitometry, 2021, 24, 591-596.	1.2	7
280	The potentially dual-faceted nature of fetuin-A in Helicobacter pylori infection and insulin resistance. Clinics, 2011, 66, 911-912.	1.5	7
281	Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents. Journal of Crohn's and Colitis, 2022, 16, 852-862.	1.3	7
282	The role of cytokines and adipocytokines in zoledronateâ€induced acute phase reaction in postmenopausal women with low bone mass. Clinical Endocrinology, 2012, 77, 816-822.	2.4	6
283	Glaucoma and Helicobacter pylori: Eyes â€œwide openâ€!. Digestive and Liver Disease, 2012, 44, 962-963.	0.9	6
284	<scp>H</scp>elicobacter pylori Infection and Serum Adiponectin. Helicobacter, 2013, 18, 321-322.	3.5	6
285	Helicobacter pylori-related metabolic syndrome might justify earlier colorectal cancer screening. Gastrointestinal Endoscopy, 2014, 80, 188-189.	1.0	6
286	Helicobacter pylori Associated With Obstructive Sleep Apnea Might Contribute to Sleep, Cognition, and Driving Performance Disturbances in Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2015, 13, 1547.	4.4	6
287	A potential impact of Helicobacter pylori infection on both obstructive sleep apnea and atrial fibrillation-related stroke. Sleep Medicine, 2017, 34, 256.	1.6	6
288	Circulating periostin in patients with nonalcoholic fatty liver disease. Endocrine, 2017, 56, 438-441.	2.3	6

#	Article	IF	Citations
289	Endocrine and metabolic disorders interplaying with non-alcoholic fatty liver disease. Minerva Endocrinology, 2017, 42, 89-91.	1.1	6
290	Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment. Hormones, 2018, 17, 573-579.	1.9	6
291	Helicobacter pylori Infection and Gastroesophageal Reflux Disease-Barrett's Esophagus-Esophageal Adenocarcinoma Sequence. American Journal of Gastroenterology, 2018, 113, 1723-1724.	0.4	6
292	Multiple Bidirectionality Brainâ€“Gut Interactions in Patients With Inflammatory Bowel Disease. Gastroenterology, 2018, 155, 1651-1652.	1.3	6
293	Of mice and men: Why progress in the pharmacological management of obesity is slower than anticipated and what could be done about it?. Metabolism: Clinical and Experimental, 2019, 96, vi-xi.	3.4	6
294	Update on the association between nonâ€alcoholic fatty liver disease andHelicobacter pyloriinfection. International Journal of Clinical Practice, 2021, 75, e13737.	1.7	6
295	Denosumab for the treatment of primary pediatric osteoporosis. Osteoporosis International, 2021, 32, 2377-2381.	3.1	6
296	Potential impact of Helicobacter pylori-related metabolic syndrome and Galectin-3 on liver, chronic kidney and brain disorders. Metabolism: Clinical and Experimental, 2021, 118, 154736.	3.4	6
297	Prevalence and determinants of type 2 diabetes mellitus in a Greek adult population. Hormones, 2016, , .	1.9	6
298	Multiple Sclerosis, Idiopathic Dilated Cardiomyopathy, and Insulin-dependent Diabetes Mellitus. Neurologist, 2011, 17, 172-175.	0.7	5
299	Active Helicobacter pylori infection on colorectal mucosa â€“ adenomatous polyp â€“ adenocarcinoma sequence. European Journal of Gastroenterology and Hepatology, 2014, 26, 243-244.	1.6	5
300	Circulating homocysteine in nonalcoholic fatty liver disease. European Journal of Internal Medicine, 2015, 26, 152-153.	2.2	5
301	Comments to the Editor concerning the paper entitled â€œThe microbiome and ophthalmic diseaseâ€•by Baim etÂal.. Experimental Biology and Medicine, 2019, 244, 430-432.	2.4	5
302	Role of autophagy in gastric carcinogenesis. World Journal of Gastrointestinal Oncology, 2021, 13, 1244-1262.	2.0	5
303	Patients with established gastro-esophageal reflux disease might benefit from eradication. Annals of Gastroenterology, 2014, 27, 352-356.	0.6	5
304	Metreleptin for the treatment of lipodystrophy: leading the way among novel therapeutics for this unmet clinical need. Current Medical Research and Opinion, 2022, 38, 885-888.	1.9	5
305	Circulating adiponectin in patients with nonalcoholic fatty liver diseaseâ€related liver fibrosis: A systematic review and a metaâ€analysis. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 1853-1864.	2.8	5
306	Sustained Clinical Inactivity and Stabilization of GH/IGF-1 Levels in an Acromegalic Patient after Discontinuation of Somatostatin Analogue Treatment. Endocrine Journal, 2008, 55, 351-357.	1.6	4

#	Article	IF	Citations
307	Normochromic normocytic anemia in a postmenopausal woman with severe osteoporosis treated with intermittent parathyroid hormone. Journal of Bone and Mineral Metabolism, 2010, 28, 108-110.	2.7	4
308	Primary hyperparathyroidism and incidental multifocal metastatic papillary thyroid carcinoma in a man. Arquivos Brasileiros De Endocrinologia E Metabologia, 2010, 54, 578-582.	1.3	4
309	Denosumab and bisphosphonates: Rivals or potential â€œpartnersâ€? A â€œhybridâ€•molecule hypothesis. Medical Hypotheses, 2011, 77, 109-111.	1.5	4
310	Helicobacter pylori and insulin resistance association: Not just a myth, not yet a fact. Saudi Journal of Gastroenterology, 2011, 17, 425.	1.1	4
311	Hpn protein as a mediator between Helicobacter pylori infection and Alzheimerâ€™s disease in sub-populations worldwide. Medical Hypotheses, 2012, 78, 349-350.	1.5	4
312	Further data on the association between Helicobacter pylori infection and primary open-angle glaucoma. Clinical Ophthalmology, 2012, 6, 243.	1.8	4
313	Sulfated oxysterols as candidates for the treatment of nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2012, 61, 755-758.	3.4	4
314	Comparative efficacy of exenatide versus insulin glargine on glycemic control in type 2 diabetes mellitus patients inadequately treated with metformin monotherapy. Advances in Medical Sciences, 2013, 58, 38-43.	2.1	4
315	Helicobacter pylori and Colorectal Cancer Riskâ€”Letter. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 365-365.	2.5	4
316	Obstructive Sleep Apnea and Environmental Contributors for Barrett's Esophagus. Clinical Gastroenterology and Hepatology, 2014, 12, 1055-1056.	4.4	4
317	Helicobacter pylori might contribute to cancer and/or bone marrow-derived stem cell-related gastrointestinal oncogenesis. Oncogene, 2015, 34, 670-670.	5.9	4
318	Association between cirrhosis and Helicobacter pylori-related brain pathologies. European Journal of Gastroenterology and Hepatology, 2015, 27, 183.	1.6	4
319	Periostin on the road to nonalcoholic fatty liver disease. Endocrine, 2016, 51, 4-6.	2.3	4
320	Helicobacter pylori eradication to prevent cardio-cerebrovascular disease: Are current data useful for clinical practice?. International Journal of Cardiology, 2017, 233, 92.	1.7	4
321	Outliers of bone metabolic diseases. Metabolism: Clinical and Experimental, 2018, 80, 1-4.	3.4	4
322	The Effect of Trimebutine and/or Helicobacter pylori Eradication on the Gastroesophageal Reflux Disease, Irritable Bowel Syndrome, and Functional Dyspepsia Overlapping Disorders. Journal of Neurogastroenterology and Motility, 2019, 25, 473-474.	2.4	4
323	Helicobacter pylori infection and diabetes mellitus. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 845-846.	3.6	4
324	Gastroesophageal reflux disease, irritable bowel syndrome and functional dyspepsia as overlapping conditions: focus on effect of trimebutine. Annals of Gastroenterology, 2019, 32, 318.	0.6	4

#	Article	IF	Citations
325	Homocysteine in nonalcoholic steatohepatitis: seemingly a paradox revisited. Journal of Gastrointestinal and Liver Diseases, 2020, 29, 270-271.	0.9	4
326	The therapeutic potential of C-C chemokine receptor antagonists in nonalcoholic steatohepatitis. Exploration of Medicine, 2020, 1, 170-183.	1.5	4
327	infection and liver cirrhosis: possible association with hepatic encephalopathy and/or post-hepatic encephalopathy cognitive impairment in patients with portal hypertension. Annals of Gastroenterology, 2014, 27, 285.	0.6	4
328	Infectious thyroiditis as a complication of fine-needle biopsy: a systematic review. Expert Review of Endocrinology and Metabolism, 2010, 5, 673-679.	2.4	3
329	Dual-Energy X-Ray Absorptiometry and Quantitative Ultrasound in Patients With Paget's Disease of Bone Before and After Treatment With Zoledronic Acid: Association With Serum Bone Markers and Dickkopf-1. Journal of Clinical Densitometry, 2010, 13, 190-196.	1.2	3
330	Modern industrialisation may increase primary open-angle glaucoma prevalence through easier transmission of Helicobacter pylori infection. Medical Hypotheses, 2011, 76, 766-767.	1.5	3
331	Editorial [Hot Topic Adiponectin in Health and Disease: Current Evidence and Therapeutic Perspectives (Guest Editor: Stergios A. Polyzos)]. Current Medicinal Chemistry, 2012, 19, 5425-5426.	2.4	3
332	Trying to treat diabetes in Greek crisis. International Journal of Clinical Practice, 2012, 66, 515-515.	1.7	3
333	Is Helicobacter pylori the usual suspect behind gastroesophageal reflux disease and dacryostenosis?. Medical Hypotheses, 2013, 81, 147.	1.5	3
334	Relationship between Helicobacter pylori infection and autoimmune disorders. Clinical Chemistry and Laboratory Medicine, 2013, 51, e73-4.	2.3	3
335	Serum visfatin in nonalcoholic fatty liver disease. Annals of Hepatology, 2014, 13, 150-151.	1.5	3
336	Nonalcoholic fatty liver disease and polycystic ovary syndrome. Annals of Hepatology, 2015, 14, 941-943.	1.5	3
337	Colchicine to decrease inflammation and fibrosis in patients with metabolic dysregulation. Medical Hypotheses, 2016, 95, 34.	1.5	3
338	Letter: Helicobacter pylori -related non-alcoholic fatty liver disease with concomitant metabolic syndrome as risk factor for colorectal neoplasia. Alimentary Pharmacology and Therapeutics, 2017, 45, 576-577.	3.7	3
339	Letter: Helicobacter pylori in lean and obese patients with nonâ€alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2017, 46, 637-638.	3.7	3
340	Potential Impact of Helicobacter Pylori on Hepatic Encephalopathy Pathophysiology. Digestive Diseases and Sciences, 2018, 63, 1087-1088.	2.3	3
341	Helicobacter pylori infection and gastrointestinal tract cancer biology: considering a double-edged sword reflection. Cellular and Molecular Life Sciences, 2019, 76, 2487-2488.	5.4	3
342	Helicobacter pylori Infection: One More Contributor to Nonalcoholic Fatty Liver Disease Pathophysiology. Journal of Clinical Gastroenterology, 2019, 53, 624-626.	2.2	3

#	Article	IF	Citations
343	Evaluation of the Direct Economic Cost per Eradication Treatment Regimen against Helicobacter pylori Infection in Greece: Do National Health Policy-Makers Need to Care?. Medicina (Lithuania), 2020, 56, 133.	2.0	3
344	A mutation in NOTCH2 gene first associated with Hajduâ€“Cheney syndrome in a Greek family: diversity in phenotype and response to treatment. Endocrine, 2021, 71, 208-215.	2.3	3
345	Helicobacter pylori, Sleeve Gastrectomy, and Gastroesophageal Reflux Disease: Is There a Relation?. Obesity Surgery, 2021, 31, 1839-1840.	2.1	3
346	Long-term statin treatment for hepatic fibrosis in patients with nonalcoholic fatty liver disease: Is it time to give the emperor a statin robe?. Metabolism: Clinical and Experimental, 2021, 121, 154796.	3.4	3
347	Impact of Helicobacter pylori-related Metabolic Syndrome and Gastroesophageal Reflux Disease on the Risk of Acute Myocardial Infarction. Journal of Neurogastroenterology and Motility, 2021, 27, 147-148.	2.4	3
348	A potential impact of Helicobacter pylori infection on minimal hepatic encephalopathy pathobiology. Journal of Gastrointestinal and Liver Diseases, 2020, 25, 405-412.	0.9	3
349	Helicobacter Pylori-Related Vitamin B12 Deficiency: A Potential Contributor in Neuropsychiatric Disorders. Indian Journal of Psychological Medicine, 2015, 37, 475-476.	1.5	3
350	Impact of Body Mass Index on the Age of Relapsing-Remitting Multiple Sclerosis Onset: A Retrospective Study. Neurology International, 2021, 13, 517-526.	2.8	3
351	Correspondence on 'Omega-3 supplementation and cardiovascular disease: formulation-based systematic review and meta-analysis with trial sequential analysis' by Rizos et al. Heart, 2022, 108, 657.1-657.	2.9	3
352	Cilofexor for the Treatment of Nonalcoholic Steatohepatitis. Current Vascular Pharmacology, 2022, 20, 111-113.	1.7	3
353	Coincidental thyroid papillary microcarcinoma in a patient treated for a toxic adenoma of the thyroid. Archives of Iranian Medicine, 2011, 14, 149-51.	0.6	3
354	Semaglutide, cilofexor, and firsocostat for nonalcoholic steatohepatitis: a dance that may need more than one dancer. Hormones, 2022, 21, 513-514.	1.9	3
355	Irritable bowel syndrome associated with mitral valve prolapse and autonomic and haemostatic abnormalities in children, adolescents and adults with migraine. Acta Neurologica Scandinavica, 2011, 123, 366-367.	2.1	2
356	Helicobacter pylori's potential association with epilepsy. Seizure: the Journal of the British Epilepsy Association, 2012, 21, 151.	2.0	2
357	Long-term effects of thyroid fine-needle biopsy on the thyroid-related biochemical parameters. International Journal of Clinical Practice, 2012, 66, 602-609.	1.7	2
358	Thyrotropin receptor autoantibodies and early miscarriages in patients with Hashimoto thyroiditis: a caseâ€“control study. Gynecological Endocrinology, 2013, 29, 793-796.	1.7	2
359	Body mass index and socioeconomic status measured in adolescence, country of origin, and the incidence of gastroesophageal adenocarcinoma in a cohort of 1 million men. Cancer, 2014, 120, 768-768.	4.1	2
360	ActiveHelicobacter pyloriinfection is associated with colorectal mucosa â€“ adenomatous polyp â€“ early and advanced adenocarcinoma sequence. Scandinavian Journal of Gastroenterology, 2014, 49, 381-382.	1.5	2

#	Article	IF	Citations
361	Additional data on Helicobacter pylori and hepatitis C virus infections and lymphoma association. European Journal of Internal Medicine, 2014, 25, e7-e8.	2.2	2
362	Bone Marrow-Derived Stem Cells in Pathogenesis of Helicobacter pylori -Associated Gastrointestinal Cancer. Clinical and Translational Gastroenterology, 2015, 6, e129.	2.5	2
363	CD44 and Helicobacter pylori-related colon oncogenesis. Journal of King Abdulaziz University, Islamic Economics, 2015, 36, 1249-1249.	1.1	2
364	Helicobacter pyloriâ€related chronic hepatitis C infection and the risk for cardiovascular disease. Liver International, 2017, 37, 1082-1082.	3.9	2
365	Low periostin levels in adult patients with Langerhans cell histiocytosis are independently associated with the disease activity. Metabolism: Clinical and Experimental, 2017, 71, 198-201.	3.4	2
366	Sixty-six years of Metabolism, Clinical and Experimental: The journey of a journal and opportunities and challenges looking ahead. Metabolism: Clinical and Experimental, 2018, 78, A4-A9.	3.4	2
367	CHAI and MACKâ€3 as noninvasive indices for nonalcoholic steatohepatitis. Liver International, 2019, 39, 1587-1587.	3.9	2
368	Metabolic syndrome components including high abdominal obesity and sarcopenia in patients with inflammatory bowel disease. Annals of Gastroenterology, 2019, 32, 214.	0.6	2
369	Vitamin D Deficiency and Unclear Abdominal Pain in Patients from Low- and Middle-Income Countries. International Journal of Environmental Research and Public Health, 2019, 16, 4607.	2.6	2
370	Impact of occupational stress on irritable bowel syndrome pathophysiology and potential management in active duty noncombat Greek military personnel: a multicenter prospective survey. European Journal of Gastroenterology and Hepatology, 2019, 31, 954-963.	1.6	2
371	Dissociating nonalcoholic steatohepatitis from hepatocellular carcinoma in obesity. Hepatobiliary Surgery and Nutrition, 2020, 9, 73-76.	1.5	2
372	A potential impact of Helicobacter pyloriâ€related sarcopenia on severity of portal hypertension. Liver International, 2021, 41, 1168-1169.	3.9	2
373	Î™risin levels in postmenopausal women with an incident hip fracture. Endocrine, 2021, 73, 719-722.	2.3	2
374	Irisin in nonalcoholic fatty liver disease: need for an updated meta-analysis. Metabolism: Clinical and Experimental, 2021, 121, 154818.	3.4	2
375	Periostin and sclerostin levels in juvenile Pagetï¿½s disease. Clinical Cases in Mineral and Bone Metabolism, 2017, 14, 269.	1.0	2
376	Effect of spironolactone on pharmacological treatment of nonalcoholic fatty liver disease. Minerva Endocrinology, 2023, 48, .	1.1	2
377	The effect of pharmacological cessation and restoration of menstrual cycle on bone metabolism in premenopausal women with endometriosis. Bone, 2022, 158, 116354.	2.9	2
378	Primary open-angle glaucoma. New England Journal of Medicine, 2009, 360, 2679; author reply 2679-80.	27.0	2

#	Article	IF	Citations
379	Impact of <scp>Helicobacter pylori</scp>â€related metabolic syndrome with hyperhomocysteinemia on extragastric pathologies. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 407-408.	2.8	2
380	Letter to the Editor Regarding â€œThe Association of Helicobacter pylori, Eradication, and Early Complications of Laparoscopic Sleeve Gastrectomyâ€•by Abeid et al.. Obesity Surgery, 2022, 32, 2079.	2.1	2
381	The effect of zoledronic acid on serum Dickkopf-1, osteoprotegerin and rankl in patients with paget's disease of bone. Bone, 2009, 44, S289.	2.9	1
382	Insulin resistance and therapy: Cross-talk between phosphatidylinositol-3 kinase and mitogen-activated protein kinase pathways. Medical Hypotheses, 2009, 72, 610.	1.5	1
383	Helicobacter pylori may be involved in stroke pathophysiology by altering tumor necrosis factor-Î± and matrix metalloproteinases. European Journal of Neurology, 2011, 18, e76-e76.	3.3	1
384	Prolonged anti-resorptive activity of zoledronic acid: evidence from postmenopausal osteopenic women and patients with Pagetâ€™s disease of bone. Clinical Rheumatology, 2011, 30, 149-150.	2.2	1
385	Association between Helicobacter pylori infection and fibromyalgia syndrome. Clinical Rheumatology, 2011, 30, 301-302.	2.2	1
386	Comment on: Jeon et al. Helicobacter pylori Infection Is Associated With an Increased Rate of Diabetes. Diabetes Care 2012;35:520â€“525. Diabetes Care, 2012, 35, e53-e53.	8.6	1
387	A rebuttal to the potential anti-tumour benefit of Helicobacter pylori-induced neutrophil-activating protein. Cancer Immunology, Immunotherapy, 2012, 61, 445-446.	4.2	1
388	Ki-67 and Bax expression in esophageal mucosa might have implications in ablative therapies for Barrettâ€™s esophagus, dysplasia, and adenocarcinoma. Surgical Endoscopy and Other Interventional Techniques, 2012, 26, 283-284.	2.4	1
389	A possible impact of common worldwide environmental agents on the prognosis of critically ill cirrhotic patients. Liver International, 2014, 34, 1127-1128.	3.9	1
390	Letter: apoptosis and hepatic fibrosis in chronic hepatitis B. Alimentary Pharmacology and Therapeutics, 2014, 39, 996-996.	3.7	1
391	Eradication of Helicobacter pylori infection might have a positive impact on subpopulations with endoscopic gastro-oesophageal reflux disease. European Journal of Gastroenterology and Hepatology, 2014, 26, 123.	1.6	1
392	Bone and Fat Interplay in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2014, 20, E22.	1.9	1
393	Prediction of atheromatic plaque evolution in carotids using features extracted from the arterial geometry. , 2015, 2015, 6556-9.		1
394	Helicobacter pylori infection and oesophageal adenocarcinoma. Cancer Epidemiology, 2016, 42, 206-207.	1.9	1
395	Helicobacter pylorion portal hypertension-related hepatic encephalopathy. Immunopharmacology and Immunotoxicology, 2017, 39, 105-106.	2.4	1
396	Obesity and the nervous system: more questions. Lancet Neurology, The, 2017, 16, 772-773.	10.2	1

#	Article	IF	Citations
397	Mild leukopenia following denosumab treatment in a woman with postmenopausal osteoporosis. Endocrine, 2018, 62, 487-489.	2.3	1
398	Adiponectin and vitamin D-binding protein concentrations are independently associated in apparently healthy women but not men: a validation cohort. Hormones, 2019, 18, 99-102.	1.9	1
399	Potential Impact of Helicobacter pylori Infection on Reflux Disease Sequence. Journal of Clinical Gastroenterology, 2020, 54, 200-201.	2.2	1
400	Adult hypophosphatasia treated with reduced frequency of teriparatide dosing. Journal of Musculoskeletal Neuronal Interactions, 2021, 21, 584-589.	0.1	1
401	Comments on â€œdose-related meta-analysis for omega-3 fatty acids supplementation on major adverse cardiovascular eventsâ€. Clinical Nutrition, 2022, , .	5.0	1
402	Spironolactone Revisited. Journal of Clinical Hypertension, 2011, 13, 783-784.	2.0	0
403	Letter: low risk of colorectal cancer in a Greek cohort of inflammatory bowel disease patients. Alimentary Pharmacology and Therapeutics, 2014, 39, 1001-1002.	3.7	0
404	P1017 : Circulating sclerostin and DICKKOPF-1 in patients with Nonalcoholic Fatty Liver Disease. Journal of Hepatology, 2015, 62, S729.	3.7	0
405	Homocysteine in nonalcoholic steatohepatitis: A reply. European Journal of Internal Medicine, 2016, 35, e40-e41.	2.2	0
406	Potential molecular aspects of Helicobacter pylori-related hyperplastic polyp development and progression. European Journal of Gastroenterology and Hepatology, 2016, 28, 851-852.	1.6	0
407	Comment on â€œTherapeutic Application of an Extract of Helicobacter pylori Ameliorates the Development of Allergic Airway Diseaseâ€. Journal of Immunology, 2018, 200, 3027.1-3027.	0.8	0
408	The relationship between Helicobacter pyloriâ€“related microbiota dysbiosis and gastrointestinal tract pathologies. Scandinavian Journal of Gastroenterology, 2019, 54, 806-807.	1.5	0
409	Letter: Helicobacter pylori in proton pump inhibitorâ€associated biliary disease. Alimentary Pharmacology and Therapeutics, 2020, 51, 313-314.	3.7	0
410	Enriched MACK-3 following CHAI and MACK-3 for the noninvasive diagnosis of nonalcoholic steatohepatitis. Annals of Hepatology, 2020, 19, 579-580.	1.5	0
411	Letter to the editor re: Li et al. (2020), â€˜The potential role of bacteria in pancreatic cancer: A systematic reviewâ€™. Carcinogenesis, 2020, 41, 539-540.	2.8	0
412	Circulating sclerostin levels during denosumab discontinuation and the subsequent early or late zoledronate infusion. Endocrine, 2021, 73, 223-225.	2.3	0
413	Impact of Helicobacter pylori-related Microbial Dysbiosis in the Pathogenesis of Metabolic Syndrome and Gastrointestinal Dysmotility Disorders. Journal of Neurogastroenterology and Motility, 2021, 27, 653-654.	2.4	0
414	Visual Vignette. Endocrine Practice, 2012, 18, 108.	2.1	0

#	Article	IF	Citations
415	Letter to the Editor: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic Acid. Journal of Clinical Endocrinology and Metabolism, 2016, 101, L89-L90.	3.6	0
416	National consensus on Helicobacter pylori infection: the next-day challenge. Annals of Gastroenterology, 2020, 33, 324-325.	0.6	0
417	Letter:Helicobacter pyloriinfection and its role in oesophageal adenocarcinoma. Alimentary Pharmacology and Therapeutics, 2020, 51, 1215-1216.	3.7	0
418	Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass. Journal of Musculoskeletal Neuronal Interactions, 2019, 19, 253-257.	0.1	0
419	Normal bone turnover markers in a patient with active Paget's disease of bone: response to treatment with zoledronic acid. Endokrynologia Polska, 2012, 63, 312-5.	1.0	0
420	Potential Impact of Active Helicobacter pylori Infection with or without Concomitant Metabolic Syndrome on Colorectal Cancer Invasion and Mortality. Israel Medical Association Journal, 2018, 20, 725-726.	0.1	0
421	GMâ€CSF as a potential candidate of a vaccineâ€induced reduction ofHelicobacter pyloriinfection. Helicobacter, 2022, 27, e12884.	3.5	0
422	Potential Impact of Active H. pylori Infection-Related Metabolic Syndrome on Preeclampsia Among Pregnant Women [Letter]. International Journal of Women's Health, 0, Volume 14, 845-846.	2.6	0